c-Myb interferes with inflammatory IL1alpha-NF-kappaB pathway in breast cancer cells

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14310%2F21%3A00118896" target="_blank" >RIV/00216224:14310/21:00118896 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00159816:_____/21:00075098

Výsledek na webu

<a href="https://doi.org/10.1016/j.neo.2021.01.002" target="_blank" >https://doi.org/10.1016/j.neo.2021.01.002</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.neo.2021.01.002" target="_blank" >10.1016/j.neo.2021.01.002</a>

Jazyk výsledku

angličtina

Název v původním jazyce

c-Myb interferes with inflammatory IL1alpha-NF-kappaB pathway in breast cancer cells

Popis výsledku v původním jazyce

The transcription factor c-Myb can be involved in the activation of many genes with protumorigenic function; however, its role in breast cancer (BC) development is still under discussion. c-Myb is considered as a tumor-promoting factor in the early phases of BC, on the other hand, its expression in BC patients relates to a good prognosis. Previously, we have shown that c-Myb controls the capacity of BC cells to form spontaneous lung metastasis. Reduced seeding of BC cells to the lungs is linked to high expression of c-Myb and a decline in expression of a specific set of inflammatory genes. Here, we unraveled a c-Myb-IL1alpha-NF-kappaB signaling axis that takes place in tumor cells. We report that an overexpression of c-Myb interfered with the activity of NF-kappaB in several BC cell lines. We identified IL1alpha to be essential for this interference since it was abrogated in the IL1alpha-deficient cells. Overexpression of IL1alpha, as well as addition of recombinant IL1alpha protein, activated NF-kappaB signaling and restored expression of the inflammatory signature genes suppressed by c-Myb. The endogenous levels of c-Myb negatively correlated with IL1alpha on both transcriptional and protein levels across BC cell lines. We concluded that inhibition of IL1alpha expression by c-Myb reduces NF-kappaB activity and disconnects the inflammatory circuit, a potentially targetable mechanism to mimic the antimetastatic effect of c-Myb with therapeutic perspective.

Název v anglickém jazyce

c-Myb interferes with inflammatory IL1alpha-NF-kappaB pathway in breast cancer cells

Popis výsledku anglicky

The transcription factor c-Myb can be involved in the activation of many genes with protumorigenic function; however, its role in breast cancer (BC) development is still under discussion. c-Myb is considered as a tumor-promoting factor in the early phases of BC, on the other hand, its expression in BC patients relates to a good prognosis. Previously, we have shown that c-Myb controls the capacity of BC cells to form spontaneous lung metastasis. Reduced seeding of BC cells to the lungs is linked to high expression of c-Myb and a decline in expression of a specific set of inflammatory genes. Here, we unraveled a c-Myb-IL1alpha-NF-kappaB signaling axis that takes place in tumor cells. We report that an overexpression of c-Myb interfered with the activity of NF-kappaB in several BC cell lines. We identified IL1alpha to be essential for this interference since it was abrogated in the IL1alpha-deficient cells. Overexpression of IL1alpha, as well as addition of recombinant IL1alpha protein, activated NF-kappaB signaling and restored expression of the inflammatory signature genes suppressed by c-Myb. The endogenous levels of c-Myb negatively correlated with IL1alpha on both transcriptional and protein levels across BC cell lines. We concluded that inhibition of IL1alpha expression by c-Myb reduces NF-kappaB activity and disconnects the inflammatory circuit, a potentially targetable mechanism to mimic the antimetastatic effect of c-Myb with therapeutic perspective.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

10603 - Genetics and heredity (medical genetics to be 3)

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Neoplasia

ISSN

1476-5586

e-ISSN

1476-5586

Svazek periodika

23

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

326-336

Kód UT WoS článku

000623868500004

EID výsledku v databázi Scopus

2-s2.0-85101178278